Role of chemotherapy in prostate cancer  

作　　者：Rita Nader Joelle El Amm Jeanny B Aragon-Ching 

机构地区：[1]Department of Internal Medicine, Lebanese American University, Beirut 1102 2801, Lebanon [2]Department of Internal Medicine, Division of Hematology and Oncology, Lebanese American University, Beirut 1102 2801, Lebanon [3]Genitourinary Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA 22031, USA

出　　处：《Asian Journal of Andrology》2018年第3期221-229,共9页亚洲男性学杂志（英文版）

摘　　要：Chemotherapy in prostate cancer （PCa） has undergone dramatic landscape changes. While earlier studies utilized varying chemotherapy regimens which were found to be largely palliative in nature and hardly resulted in durable or meaningful responses, docetaxel resulted in the first chemotherapy agent that showed improvement in overall survival in metastatic castration-resistant prostate cancer （mCRPC）. However, combination chemotherapy or any agents added to docetaxel have failed to yield incremental benefits. The improvement in overall survival as well as secondary endpoints of prostate-specific antigen （PSA） and time to recurrence when using docetaxel in the metastatic hormone-sensitive state has changed the standard of care for treatment of newly diagnosed de novo metastatic PCa. There are also promising results in locally advanced PCa and high-risk PCa in both the neoadjuvant and adjuvant settings. This review summarizes the historical as well as the more contemporary use of chemotherapeutic agents in PCa in varying states and phases of disease.Chemotherapy in prostate cancer （PCa） has undergone dramatic landscape changes. While earlier studies utilized varying chemotherapy regimens which were found to be largely palliative in nature and hardly resulted in durable or meaningful responses, docetaxel resulted in the first chemotherapy agent that showed improvement in overall survival in metastatic castration-resistant prostate cancer （mCRPC）. However, combination chemotherapy or any agents added to docetaxel have failed to yield incremental benefits. The improvement in overall survival as well as secondary endpoints of prostate-specific antigen （PSA） and time to recurrence when using docetaxel in the metastatic hormone-sensitive state has changed the standard of care for treatment of newly diagnosed de novo metastatic PCa. There are also promising results in locally advanced PCa and high-risk PCa in both the neoadjuvant and adjuvant settings. This review summarizes the historical as well as the more contemporary use of chemotherapeutic agents in PCa in varying states and phases of disease.

关 键 词：DOCETAXEL metastatic castration-resistant prostate cancer prostate cancer 

分 类 号：Q959.837[生物学—动物学] S896.3[农业科学—特种经济动物饲养]